Featured image: Palantir’s stand at the NHS Confederation conference in June 2022 (file photo). Photo: Rathfelder, Wikimedia Commons, CC BY-SA 4.0. Cropped to 16:9.
NHS England has deleted a website claim that 137 hospital trusts were benefiting from the Palantir NHS contract, The Guardian reported on Thursday, Nov. 12, 2026. Twenty-nine trusts listed as realising benefits from the £330 million Federated Data Platform had said they were not using the system or its applications.
Contract values are from the Contracts Finder award notice and NHS England’s Federated Data Platform frequently asked questions, updated April 14, 2026. The 137 and 29 figures are from The Guardian’s Nov. 2 and Nov. 12 reports.
A £330 million contract with a 2027 decision point
NHS England awarded the Federated Data Platform and Associated Services contract to Palantir Technologies UK, Ltd. on Nov. 22, 2023, according to the government’s Contracts Finder award notice, which lists the same day as the contract start date and Feb. 15, 2027, as the end date. The published value is £182,242,760. The notice says that figure is not a committed amount: NHS England pays for platform services as they are used, and the value “could increase to a forecasted amount of £330m,” which is also not a committed spend.
NHS England’s own frequently asked questions, updated April 14, 2026, describe the contract as valued at £330 million over a maximum of seven years and say it can fund up to 240 NHS organisations, including trusts and integrated care systems. The same page says only a three-year term is committed, after which the contract “can be extended by two years and then two further one year periods.” A May 2026 parliamentary written answer said ministers had been told the initial term ends in March 2027 and that a decision would be needed on an extension. The Boston Report is reporting both the Feb. 15, 2027, date on the award notice and the March 2027 wording used in that official answer; it is not treating them as the same day.
The platform is built on Palantir’s Foundry software. NHS England says it remains the data controller for the national instance, that each trust and integrated care board controls its own instance, and that Palantir may not commercialise NHS data or use it to train its own products. The stated aims include helping staff manage waiting lists, schedule operations and speed up hospital discharges. In its frequently asked questions, NHS England also says its Medium Term Planning Framework for 2026/27 to 2028/29 sets an expectation that providers and integrated care boards onboard to the platform and start using core products by 2028/29.
Palantir Technologies Inc. (NASDAQ: PLTR) is a U.S. software company. In early November it reported that U.S. commercial revenue had surpassed U.S. government revenue for the first time. The NHS platform is a separate, non-U.S. government contract and is Palantir’s largest public-sector deal in the United Kingdom.
By the numbers: listed uptake and the 29 trusts
On a page for acute trusts, NHS England says 170 hospital trusts had signed up to the Federated Data Platform as of May 2026. That is 70.8% of the 240 organisations the contract is described as able to fund, according to a Boston Report calculation from those two official figures. Sign-up is not the same as live use, and the 170 figure has not been updated on that page since May.
On Nov. 2, The Guardian reported that NHS England’s website stated 137 trusts were “live” with the platform, and that 29 of the trusts described as “realising benefits” had said, in freedom-of-information responses compiled by the campaign group Medact, that the system was not live or that they were not using any of its applications. Epsom and St Helier said it was “not using FDP at the moment.” Kent and Medway said “the FDP is not currently live.” Mersey Care said it had “not yet gone live with the FDP.” Nottingham University Hospitals said “no implementation timeline has been agreed.” University Hospitals of North Midlands said, “FDP is not live. We do not intend to roll it out in the future.”

Twenty-nine is 21.2% of the 137 trusts The Guardian said were listed as live, a Boston Report calculation from those reported figures. That share cannot be inverted to say the other 108 trusts are active users. The Guardian and Medact did not publish a complete tally of every freedom-of-information reply, and some organisations may have given other answers or none at all.
Asked about the “realising benefits” list in early November, NHS England said nearly 140 trusts “have now reported benefits from the wide range of tools available on the platform.” The Guardian reported that the list has included trusts using the tools for back-office data analysis and submission rather than to support patient care. Torbay and South Devon NHS Foundation Trust, the newspaper said, stated it was “not currently operationally using the FDP,” while NHS England recorded it as live because infrastructure was in place “to support data submission, rather than active operational use of FDP apps.”
On Nov. 12, The Guardian reported that the original list of trusts had been taken down and replaced with a less detailed page saying early users were “already seeing real results – reduced admin, faster patient pathways, and more time for care.” NHS England did not respond to the newspaper’s requests for comment on that take-down. The Boston Report was not able to reload the official uptake-and-benefits listing pages on Nov. 15; the 137 figure above is therefore attributed to The Guardian’s account of what the NHS site showed in early November, not to a fresh copy of that list.
Benefits claims and the statistics watchdog
The dispute over how many trusts are using the platform sits on top of an earlier argument about what the software has achieved. On Nov. 2, a Palantir spokesperson told The Guardian: “Palantir software is helping to deliver better care, with trusts using it recording 117,000 additional operations, a 14.3% reduction in discharge delays for long stay patients and a 5.6% improvement in the number of people finding out whether or not they have cancer within 28 days.” Those figures are Palantir’s characterization of NHS performance metrics. They are not an independent finding of cause and effect.
In a public statement on July 22, 2026, the Office for Statistics Regulation said NHS England had added a caveat that it “cannot therefore draw conclusions about cause and effect as other variables have not been controlled for” to before-and-after comparisons on the Federated Data Platform benefits pages. The regulator said those comparisons are observational and welcomed NHS England’s commitments to label them more clearly, to commission an independent evaluation by Imperial College focused first on the Inpatients and OPTICA products, and to publish trust-level benefits data on a schedule. The Office for Statistics Regulation also said it would monitor future uses of the figures, including in ministerial briefing. On Nov. 2, The Guardian reported that the regulator said it would take the “realising benefits” claim forward under its casework function. On Nov. 12, the newspaper said the regulator was examining NHS claims about the extent of the system’s use.
Labour MP Ben Coleman, a member of the Commons health and social care select committee, told The Guardian it was “troubling” that NHS England had listed 137 trusts as benefiting and then “apparently pulled the list when 29 said they weren’t using all or most of it.” He said, “When NHS England makes claims like this without checking them, it destroys trust – and it has happened before.” Chi Onwurah, chair of the Commons science and technology committee, said after the Nov. 2 report: “If many NHS trusts don’t see the value of the FDP, serious questions need to be asked about whether the hype surrounding Palantir’s products matches reality.” Marc Farr, chair of the NHS Chief Data and Analytics Officers Network, said it was “crucial for public support … that benefits are reported accurately, transparently and in a way that can be properly verified.”
No official decision yet on a 2027 extension
The Guardian reported on Nov. 12 that ministers were weighing whether to extend the £330 million contract to 2029, and that it had been reported the previous week that ministers planned to extend the deal. Campaign groups including the Doctors Association UK, Medact, Amnesty UK and Just Treatment wrote this week to Prime Minister Andy Burnham and Health Secretary Yvette Cooper opposing a reported plan to give Palantir two more years while a U.K.-based alternative is prepared, the newspaper said. Those groups argued the deal could be ended in 2027 using a “termination assistance period” in the contract. The government has not issued a formal public decision in the sources reviewed for this article. Palantir has hired Labour peer Tom Watson as a U.K. lobbyist; The Guardian reported that he recently wrote to Cooper saying Palantir wanted to help “build Britain’s sovereign technological capability.”
Palantir’s U.K. and Europe chief executive, Louis Mosley, has said ending the contract would be “putting politics above patients,” The Guardian reported. Andrea Egan, general secretary of the health workers’ union Unison, told the newspaper that any decision to extend the deal would be “completely unacceptable and a betrayal of staff and patients.” Some opponents also object to Palantir’s other government work, including contracts for militaries and U.S. immigration authorities; The Boston Report has previously examined Palantir’s defense software claims and U.S. military contracts.
The NHS fight is not Palantir’s only new public-sector work in Britain this month. The Register reported on Nov. 13 that three police forces in eastern England — Bedfordshire, Cambridgeshire and Hertfordshire — had awarded Palantir a five-year, £10.1 million Foundry contract running until October 2031. PublicTechnology, reporting on Nov. 10, said the agreement was signed in October and that Cambridgeshire was the lead buyer. The Register also reported that London Mayor Sadiq Khan had blocked a separate £50 million Metropolitan Police contract, that Palantir sued, and that the case was settled in October, and that former Metropolitan Police commissioner Dame Cressida Dick has been a paid adviser to Palantir since September 2025.
At the Friday, Nov. 13, close of $1.3211 per pound, from Exchange Rates UK market data, the £330 million forecast ceiling equals about $436 million, and the published £182.2 million award equals about $241 million, according to Boston Report calculations. Those dollar figures are conversions, not amounts billed in dollars, and they change with the exchange rate. The immediate facts on the contract are narrower: NHS England has removed a public list of trusts it had described as benefiting from Palantir’s platform, 29 listed trusts told a freedom-of-information survey they were not using the system or its applications, and a decision on whether the initial term is extended is due in early 2027.
Sources
- The Guardian: “NHS England deletes ‘misleading’ claim 137 trusts benefiting from Palantir AI tools,” Nov. 12, 2026
- The Guardian: “Palantir AI tech unused or little used by 29 NHS trusts said to be benefiting from it,” Nov. 2, 2026
- UK Contracts Finder: Federated Data Platform and Associated Services award notice
- NHS England: Federated Data Platform frequently asked questions, updated April 14, 2026
- NHS England: Information for acute trusts (170 hospital trusts signed up as of May 2026)
- Office for Statistics Regulation: statement on NHS England Federated Data Platform performance metrics, July 22, 2026
- UK Parliament written answer UIN 222, May 2026, on the contract term and extension decision
- The Register: “Palantir adds three UK police forces to its beat with £10.1M deal,” Nov. 13, 2026
- PublicTechnology: “Eastern police forces sign £10m Palantir deal to support safeguarding,” Nov. 10, 2026
- Exchange Rates UK: GBP/USD market close of $1.3211 on Nov. 13, 2026
Read next in Artificial Intelligence
Artificial IntelligenceTesla Opens Cybercab Orders at $29,990, but It Won’t Move Without a $299 Monthly Subscription
Artificial IntelligenceNvidia CEO Huang resigns as shares plunge 13% at the open
Artificial IntelligenceGeoffrey Hinton: The Life and Work of the ‘Godfather of AI’ Who Now Warns About It
Most read this week
- Finland Confirms Strike on Russian Warship in Gulf of Finland; Ukraine’s SBU Claims Drone Attack
- U.S. Envoys Witkoff and Kushner Hold Talks With Putin in Moscow, Then Head to Dublin to Brief Zelensky
- Israeli Strike on Gaza’s Nasser Hospital Kills Six, Including a Surgeon, Health Ministry Says
- Nvidia Board Hires Wachtell’s Joon Kim to Lead Huang Probe as Shares Fall 5.47% and an Investor Sues
- Drones Kill Workers at Zaporizhzhia Nuclear and Thermal Plants, IAEA Says, as Russian Strikes Hit 5 Substations
Latest
- ‘Democracy Files’ Leak Alleges Plan to Declare U.S. Government Illegitimate After Midterms
- Nvidia Earnings, Walmart and Fed Minutes Headline a Busy Week for Wall Street: What to Watch Nov. 16-20
- Canada’s Budget 2026 Projects a $62.3 Billion Deficit After a $158 Billion Fiscal Improvement
- Family Dollar to Pay $63 Million, Including $40 Million for Shoppers, to Settle FTC Overcharging Claims
- Canada’s Trade Surplus Hits a Four-Year High of $5.35 Billion as Energy and Gold Mask Tariff Hits
Get The Boston Report Briefing
Our free weekly email with the most important stories from Boston and the world. Unsubscribe anytime.
Free. We never sell your address. Privacy policy